ABSTRACT Objectives: To assess the extent to which stage at diagnosis and adherence to treatment guidelines may explain the persistent differences in colorectal cancer survival between the USA and Europe.
▪ The stage at diagnosis varied more widely between the participating European countries than between the participating US states. ▪ Evidence-based guidelines do not seem to have been closely followed. The proportion of patients who received surgery with adjuvant chemotherapy and/or radiotherapy was much lower in Europe than in the USA. Elderly patients received surgery, chemotherapy or radiotherapy less often than younger patients, despite evidence that they could have benefited. ▪ The wide US-Europe differences in 5-year net survival from colorectal cancer in the late 1990s were probably attributable to the earlier stage and more extensive use of surgery and adjuvant treatment in the USA. Lower survival in Europe was mainly attributable to the much lower survival in Eastern countries. This study underlines the need for population-based survival estimates derived from systematic clinical records of stage and treatment for all patients.
INTRODUCTION
Five-year relative survival from cancers of the colon and rectum has been reported as 12-14% higher in the USA than in Europe. 1 Survival for patients diagnosed during 1985-1989 was higher in each of the 9 US states and metropolitan areas covered at that time by the Surveillance, Epidemiology and End Results (SEER) Program than in any of the 22 European countries participating in the EUROCARE-2 study. 2 The differences in 3-year colorectal cancer survival for patients diagnosed during 1990-1991 between 10 territories in five European countries and the nine SEER areas were mainly attributable to the stage at diagnosis. 3 The first worldwide analysis of cancer survival (CONCORD 1 ) provided a systematic comparison of survival for adults (15-99 years) diagnosed with cancer of the breast, colon, rectum or prostate in 31 countries during 1990-1994 and followed up to 1999. International differences in age-standardised survival were very wide, even after adjustment for differences in mortality from other causes of death. Colorectal cancer survival was higher in the USA and Canada than in many other countries. Differences between the USA and most European regions were smaller than for patients diagnosed during [1985] [1986] [1987] [1988] [1989] . 2 The largest differences were between the USA and Eastern Europe.
The CONCORD protocol incorporated studies designed to explain the international variations in survival. These 'high-resolution' studies involve the systematic collection of detailed clinical and pathological data that are not routinely abstracted by population-based cancer registries from the original medical records of large random samples of patients. The high-resolution study reported here provides a transatlantic comparison of stage, treatment and survival for patients with colorectal cancer.
The aims were (1) to compare the distributions of stage for colorectal cancers in Europe and the USA; (2) to determine whether the transatlantic differences in survival persist and, if so, to assess the extent to which they are attributable to differences in stage at diagnosis and (3) to compare adherence to 'standard care' 4 for colorectal cancer in relation to age, stage and cancer site between the USA and Europe.
MATERIAL AND METHODS
Data on stage, diagnostic procedures, treatment and follow-up were collected for a representative sample of about 13 000 patients aged 15-99 years diagnosed with colorectal cancer (International Classification of Diseases, ninth revision (ICD-9) 5 codes 1530-1539, 1540-1549) in the USA and Europe during 1996-1998. A single protocol was used, derived from the EUROCARE high-resolution protocols. 6 The European data were provided by 14 populationbased cancer registries in nine countries, four with national coverage (denoted below with an asterisk (*)). For some analyses, the data were grouped into the four European regions defined by the United Nations (UN, http://unstats.un.org/unsd/methods/m49/m49regin. htm)-Northern Europe: Finland*; Western Europe: France (Côte d'Or) and the Netherlands (North East Netherlands); Southern Europe: Italy (Genova, Ragusa and Varese), Slovenia* and Spain (Granada, Navarra and Tarragona); Eastern Europe: Estonia*, Poland (Cracow and Kielce) and Slovakia*. Estonia is classified by the UN as being in Northern Europe, but cancer survival has resembled that in Eastern European countries 7 and Estonia was included here with Eastern Europe. US data were provided by seven statewide registries (California, Colorado, Illinois, Louisiana, New York, Rhode Island and South Carolina) from the National Program of Cancer Registries (NPCR), based at the Centers for Disease Control and Prevention.
For this study, cancer registries in the EUROCARE-3 high-resolution study 8 updated follow-up to at least 5 years after diagnosis for all patients. North East Netherlands was not included in EUROCARE-3, but the registry routinely collects high-resolution data and could provide such data on virtually all patients with colorectal cancer.
Most registries provided a random sample of at least 500 patients diagnosed during 1996-1998 (1997 in the USA). The Finnish cases were a population-based sample of patients diagnosed in the Tampere hospital region, which is considered representative of Finland.
Of the 12 941 anonymised records for patients with a malignant neoplasm of the colon or rectum, 418 were excluded: in situ (396, 3.1%: collected in the USA, but not in Europe); unknown sex (22, 0.2%); benign or uncertain behaviour (1), or age less than 15 or 100 years ARTICLE SUMMARY Strengths and limitations of this study ▪ To our knowledge, this is the first population-based highresolution study with a direct US-Europe comparison of colorectal cancer survival, using clinical data on investigation and treatment collected directly from medical records by trained abstractors with a single protocol, which was then subjected to standard quality control procedures and analysed centrally with the same statistical methods. Some of these clinical records of investigation, stage and treatment are not complete, systematic or timely because they are not collected through routine cancer surveillance reporting for all patients with cancer. ▪ Most of the diagnostic and therapeutic approaches used in the late 1990s remain in widespread use; mesorectal excision for rectal cancer is more recent. It remains relevant to understand the extent to which investigation and treatment are responsible for the persistent international differences in colorectal cancer survival. ▪ The modelling approach to estimate net survival is a methodological strength. ▪ Northern Europe was represented only by Finland. or over (19, 1.5% 
Statistical analysis
We analysed the distribution of stage and the number of lymph nodes examined pathologically. 9 We report the proportion of patients resected with curative intent and the distributions of stage-specific treatment for colon or rectal cancer. Data sets were excluded if data on stage and/or treatment were missing for 25% or more of patients: Ragusa was excluded from stage-specific analyses, including those on treatment related to the stage at diagnosis.
Net survival up to 5 years after diagnosis was estimated by geographical area (UN region of Europe, country, registry or US state), age and stage, using flexible parametric excess hazard models. 10 Net survival is the survival of patients with cancer in the hypothetical situation where the cancer may be assumed to be the only possible cause of death; it may be interpreted as cancer survival after controlling for competing causes of death. Net survival was estimated with a modelling approach [10] [11] [12] in which the total hazard of death is considered as the sum of the cancer-related mortality hazard (excess hazard) and the hazard of death from other causes (background hazard). The background hazard is derived from life tables of all-cause mortality by sex, single year of age and calendar year in the general population of the geographical area from which the patients with cancer are drawn. We constructed period life tables for 1994-2004 with the approaches proposed by Baili et al.
13
Age was included as a continuous variable in all models, in order to avoid the bias in the estimation of net survival that would otherwise arise from differential loss of the oldest patients to competing hazards of death (informative censoring). The non-linear and timedependent (interaction with time since diagnosis) effects of age were initially modelled with cubic splines. The proportionality of the effect of tumour stage on the excess hazard was also assessed. Simpler models, with linear and/or proportional effects, were successively tested and selected using the Akaike information criterion for goodness of fit.
14 We also estimated the instantaneous excess risk (hazard) of death due to colorectal cancer, after subtracting the hazard from all other causes of death.
10-12 15 16 We present the mean excess hazard per 1000 person-years at risk at selected times since diagnosis (1 and 6 months, and 1, 3 and 5 years), by age group as well as by stage at diagnosis, after adjustment for age.
The overall (all ages) net survival estimates were age standardised with the International Cancer Survival Standard (ICSS) weight. 17 We used a logistic regression model to estimate the odds of patients with colorectal cancer in each area being resected with curative intent, the odds of patients with colon cancer at Dukes' stage B or C receiving chemotherapy, and the odds of patients with rectal cancer with Dukes' stage A-C being treated with radiotherapy, after adjustment for age and/or tumour site and/or sex.
Survival analyses were performed with stpm2 15 in Stata V.12 (StataCorp LP, College Station, Texas, USA).
RESULTS
We included 12 523 patients with an invasive, primary colorectal cancer: 9186 patients in 14 registries in nine European countries and 3337 patients in seven US states (table 1). Microscopic verification was available for 96-98% of the patients in each of the US states and 93% in Europe, ranging from 85% in Ragusa (Italy) to 99% in Kielce (Poland). The proportion of patients with colorectal cancer who were men was similar in Europe (53%) and the USA (50%), but colon cancer was more frequent in the USA (73%) than in Europe (60%). Data were available on stage at diagnosis for 90-93% of patients on both sides of the Atlantic, ranging from 76% (Finland) to 95% or more in 3 of the 14 European registries and from 90% (Colorado and South Carolina) to 97% (Louisiana) in the USA.
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Resection for curative intent was more frequent in the USA (85%) than in Europe (75%). The proportion resected with curative intent was remarkably similar in all seven US states (84-88%). Only Western Europe (84%) showed a proportion as high as that in the USA.
Thirty-day postoperative mortality was 5% or less in the USA and Europe. Among patients resected with curative intent, the proportion with a known stage was around 95% in the USA and Europe, with the lowest proportions in Northern Europe (84-90%; table 2). In many European registries, data on the number of lymph nodes examined after surgery were not available for most patients (see web-appendix table S1).
Adjuvant chemotherapy and radiotherapy were administered more frequently in the USA than in Europe (table 3). Among Dukes' B patients with colon cancer, 28% received chemotherapy in the USA (21-46%) vs 20% in Europe (4-31%). Among Dukes' C patients with colon cancer, 56% received chemotherapy in the USA (47-64%) vs 47% in Europe (38-53%). Among Dukes' A-C patients with rectal cancer, 47% received radiotherapy in the USA (41-52%) vs 37% in Europe (26-45%).
Relative Older patients were only 10% as likely to be treated with radiotherapy and chemotherapy.
Overall, age-standardised net survival at 5 years was 50% in Europe and 58% in the USA (figure 1). Survival was lower in all European areas than in the USA, and only in Northern Europe was the figure (56%) close to that in the USA. Survival was lower in Western Europe (54%) and in Southern Europe (49%) and lowest in Eastern Europe (42%). Survival varied widely not only between European countries (from 56% in France and Finland to 37% in Poland), but also between US states (from 64% in Rhode Island to 56% in Illinois and 50% in South Carolina).
Five-year age-standardised net survival was higher in the USA than in Europe for Dukes' stage A (84%) and B (75%) tumours, but higher in Northern Europe than in the USA for Dukes' C (52%) and D (12%) tumours (figure 2). The geographical range in survival was much wider for locally advanced disease, from 36% in Eastern Europe to 77% in Northern Europe and 49% in the USA. As with overall survival, stage-specific 5-year survival was similar in Northern, Western and Southern Europe and the USA. In Eastern Europe, survival for nodepositive, locally advanced and metastatic tumours was lower than in other European regions and the USA.
Survival was 5-12% higher in women than in men in all areas, especially in Northern and Western Europe (11-12%; see web-appendix figure S1 ).
The mean excess hazard of death at 1 and 6 months, and at 1, 3 and 5 years after diagnosis was higher in Eastern Europe than in all other regions, for all ages combined as well as in each of the three age categories (see web-appendix figure S2). The difference was most marked for elderly patients (75-99 years). No striking differences were found between Northern, Western and Southern Europe and the USA. The high excess hazard of death in Eastern Europe was mainly confined to patients with Dukes' D tumours (see web-appendix figure S3 ).
DISCUSSION
Transatlantic differences in population-based colorectal cancer survival have raised questions about early diagnosis and the adequacy of investigation and treatment that cannot be addressed with data from clinical trials, which include only selected patient groups.
Patterns-of-care studies and survival studies have been conducted separately in Europe 3 6 8 and the USA. 18 19 To our knowledge, this is the first population-based highresolution study that allows direct comparison of colorectal cancer survival between Europe and the USA with clinical data on investigation and treatment collected directly from medical records by trained abstractors with a single protocol, which is then subjected to standard quality control procedures and analysed centrally with the same statistical methods. The participating cancer registries are populationbased registries that register all persons diagnosed in the territory they cover. This study included large, randomly selected subsets of all persons diagnosed with colorectal cancer during 1996-1998 in each territory. These samples are not intended to be 'representative' of all patients with colorectal cancer in Europe or the USA, but they are representative of all patients with colorectal cancer diagnosed during 1996-1998 in the territory of each registry and the findings are generalisable to the populations from which they are drawn.
Most of the diagnostic and therapeutic approaches used in the late 1990s remain in widespread use. Understanding their role in international differences in survival remains relevant. Mesorectal excision for rectal cancer is the main exception: it has improved survival from rectal cancer 20 21 but its widespread use is more recent. Mesorectal excision was not used in Estonia before 1997, which may partly explain the low survival from rectal cancer. 22 The transatlantic 12% difference in the 3-year survival in colorectal cancer survival for patients diagnosed during 1990-1991 3 was mostly attributed to the differences in stage at diagnosis. In our study of patients diagnosed in the late 1990s, the overall 5-year net survival was still higher in the 7 US states (58%) than in the 14 European regions (42-56%). The widest differences with the USA were seen in Southern (49%) and Eastern Europe (42%).
The two studies differed in design, however: data from the SEER public-use data set in the USA 23 were simply adapted to the EUROCARE-2 high-resolution protocol as far as possible. In contrast, data for this study were collected directly from clinical records on both sides of the Atlantic, with a standard protocol. US coverage changed from the five metropolitan areas and four states covered by the SEER Program to seven of the state-wide NPCR registries. In the earlier study, differences in background mortality in the USA were controlled with a single national life table for 1990, weighted for the proportion of African-American patients, white patients and other races. Here, we were able to use state-specific life tables for each of the calendar years 1996-2004.
The tighter control for background mortality and the modelling approach used to estimate net survival are the methodological strengths of this study, but these changes do not explain why the transatlantic differences we observed in 5-year survival are smaller than the differences in 3-year survival for patients diagnosed in the early 1990s. 3 Survival varied widely not only among European countries, but also between the seven US states. Survival in Slovenia was lower than in other Southern European The mean excess hazard of death up to 5 years after diagnosis was similar in Europe and the USA for patients with tumours in Dukes' stage A or B. The hazard was somewhat higher in Eastern Europe for Dukes' stage C and much higher for Dukes' D disease, especially in the first 3 years after diagnosis. The very high hazard of death for patients with late-stage disease in Eastern Europe suggests that fewer effective treatment options were available for these patients, although higher levels of comorbidity may also have restricted the choice.
It was not possible to evaluate the impact of the number of examined lymph nodes on the stage-adjusted excess hazard of death, because information on nodal status was so often unavailable (see web-appendix). It is therefore impossible to assess whether stage migration affects the comparison of stage-specific survival between European regions and the USA in the late 1990s, as reported for patients diagnosed in 1990. 3 We did not have information on whether or not patients in this study had undergone faecal occult blood testing or sigmoidoscopy before diagnosis. Opportunistic testing with these procedures was common in the USA in the late 1990s. Almost 40% of respondents to the Behavioural Risk Factor Surveillance System (http:// www.cdc.gov/mmwr/preview/mmwrhtml/00056494. htm) survey in 1997 reported having had a faecal occult blood test at some time in the past and 42% reported a previous sigmoidoscopy or proctoscopy. Removal of premalignant polyps or in situ neoplasms may thus have been more frequent than in Europe. This would be expected to reduce incidence, shift the spectrum of malignancy to the right and reduce survival in the USA. In fact, incidence in the USA is higher, the stage distribution is less advanced, and survival is higher than in Europe.
Adjuvant chemotherapy for colon cancer and adjuvant radiotherapy for rectal cancer were used more widely in the USA than in Europe. Despite the evidence available in the late 1990s on the lack of efficacy of adjuvant chemotherapy for Dukes' B colon cancer, 30% of patients with colon cancer received it in the USA, and 20% overall in Europe. In Finland and Western Europe, however, adjuvant chemotherapy was rare, in line with the contemporary recommendations, while in Southern and Eastern Europe, adjuvant chemotherapy was used as frequently as in the USA.
In contrast, there were striking differences in the use of adjuvant chemotherapy for Dukes' C stage colon cancer in the late 1990s, particularly within Europe. Given the wide consensus on its effectiveness since 1990, we did not expect to find that such a strong recommendation would be so poorly followed. Comorbidity and greater toxicity are not valid reasons for the underuse of adjuvant chemotherapy in the elderly: toxicity is not greater 24 25 and quality of life is not worse. 26 Elderly patients were 90% less likely to receive adjuvant chemotherapy than younger patients. Clinical attitudes appear to differ between the USA and Europe, where the proportion of patients receiving adjuvant chemotherapy is much lower. This suggests that a higher proportion of older patients with Dukes' C colon cancer who are fit enough to undergo surgery should receive adjuvant chemotherapy, particularly in Europe.
Radiotherapy is known to be an effective complement to surgery for rectal cancer, in particular to reduce the risk of local recurrence; preoperative radiotherapy is preferable to postoperative radiotherapy 27 and it is recommended in Europe and the USA. [28] [29] [30] [31] We were unable to distinguish between the impact of preoperative and postoperative radiotherapy, because this information was not systematically available, but fewer patients received radiotherapy in Europe than in the USA and the practice in Europe was strikingly heterogeneous, even within a given country. Age was a strong predictor of the use of radiotherapy. Some older patients are unsuitable for radiotherapy because of comorbidity, but their 70% lower odds of receiving it cannot be explained by comorbidity alone; radiotherapy has not yet been deployed to its full potential for older patients with rectal cancer. It is not clear why the evidence on the benefits of radiotherapy was so poorly followed in many regions.
Surgical resection offers the only approach to a definitive cure for colorectal cancer. The proportion of patients resected with curative intent was very similar in the seven US states (84-88%), but it varied widely between the nine European countries (from 56% to 86%) and was particularly low in Eastern Europe (mean 62%). A more aggressive approach to surgical treatment for elderly patients with colorectal cancer in Europe could improve this situation, although European patients were more often diagnosed at an advanced stage or with unresectable disease. Performance status and comorbidity can influence whether a patient is considered fit for resection, but data on these factors were not available. The quality of life in Canadian patients aged over 80 years who underwent surgery for colorectal cancer was generally comparable to that of younger patients. 32 In this large, population-based study in Europe, however, age alone often seems to have been a limiting factor in the treatment of colorectal cancer. Elderly patients were generally treated less often with surgery, chemotherapy or radiotherapy, despite the evidence that they could benefit from these treatments. Treatment decisions should be taken in the context of multidisciplinary meetings, including a comprehensive geriatric assessment: age alone should not exclude a patient from receiving surgery and/or adjuvant treatment.
Differences in colorectal cancer survival between Europe and the USA in the late 1990s were still wide and may be attributable to the earlier stage at diagnosis, higher levels of surgery and more extensive use of adjuvant treatment in the USA.
Evidence-based guidelines do not seem to have been followed as closely as they should be: chemotherapy was used too often for Dukes' B disease and not often enough for Dukes' C disease, especially among elderly patients.
The need for population-based survival estimates derived directly from the clinical records on the stage at diagnosis and treatment is recognised by clinicians and epidemiologists. A recent comparison of stage-specific cancer survival with population-based data 33 was complicated by inconsistent coding of the stage 34 ; several registries had to be excluded because fewer than half the tumour records contained data on stage. In this highresolution study, the stage data were remarkably complete (76-94% in Europe and 93% in the USA), because they were collected directly from clinical records. Ideally, the medical records of patients with cancer would systematically include data on investigations and stage at diagnosis; cancer registries would obtain those data for all patients and the stage would be coded consistently. Until then, high-resolution studies would appear to offer the most reliable approach to obtain data on stage and treatment, and to assess survival by stage at diagnosis.
If good evidence is required on whether all patients receive guideline-compliant investigation and treatment, and whether this makes a difference to survival, then cancer registries will need to be able to obtain timely and high-quality data on the investigations, the stage and the treatment for all patients with cancer. 
